Profil
Ann-Sofie Sternås is currently working as the Director of Intellectual Property at Akinion Pharmaceuticals AB. Previously, she held positions as the Director of Intellectual Property at Axelar AB, Principal at AstraZeneca AB, and Vice President of Intellectual Property Rights at ClanoTech AB.
Postes actifs de Ann-Sofie Sternås
| Sociétés | Poste | Début |
|---|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Corporate Officer/Principal | - |
Anciens postes connus de Ann-Sofie Sternås
| Sociétés | Poste | Fin |
|---|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Corporate Officer/Principal | - |
Axelar AB
Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Corporate Officer/Principal | - |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
Axelar AB
Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Health Technology |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer and macular degeneration | Health Technology |
















